Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
18 mrt 2016 - 07:30
Statutaire naam
Galapagos NV
Titel
Results from 10-week analysis of Phase 2 study with filgotinib in Crohn's Disease presented at ECCO
Bericht
Mechelen, Belgium; 18 March 2016: Galapagos (Euronext & NASDAQ: GLPG) announces the presentation of detailed results from the Phase 2 FITZROY study of filgotinib in Crohn's Disease, at the 11th Congress of ECCO in Amsterdam, the Netherlands, from March 16 - 19.
Prof Dr Séverine Vermeire, the principal investigator of the FITZROY study, will be presenting the results on the 10-week on treatment analysis. These results from this 174-patient study were reported in December 2015 and indicated that the study achieved the primary endpoint of clinical remission: the percentage of patients achieving a Crohn's Disease Activity Index (CDAI) score lower than 150 was statistically significantly higher in patients treated with filgotinib versus patients receiving placebo (48 percent (61/128) vs. 23 percent (10/44), p<0.05).
Datum laatste update: 19 december 2025